María Victoria
Mateos Manteca
Profesora Titular de Universidad
![Foto de María Victoria](/img/nophoto.png)
![Foto de Hospital Morales Meseguer](/img/noimage_org.png)
Hospital Morales Meseguer
Murcia, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Morales Meseguer (51)
2024
2023
-
Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma
Blood, Vol. 142, Núm. 18, pp. 1518-1528
-
Randomized phase II study of weekly carfilzomib 70 mg/m2 and dexamethasone with or without cyclophosphamide in relapsed and/or refractory multiple myeloma patients
Haematologica, Vol. 108, Núm. 10, pp. 2753-2763
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Lenalidomide-dexamethasone versus observation in high-risk smoldering myeloma after 12 years of median follow-up time: A randomized, open-label study
European Journal of Cancer, Vol. 174, pp. 243-250
-
Prognostic Value of Serum Paraprotein Response Kinetics in Patients With Newly Diagnosed Multiple Myeloma
Clinical Lymphoma, Myeloma and Leukemia, Vol. 22, Núm. 9, pp. e844-e852
2021
-
Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma (Annals of Hematology, (2020), 99, 8, (1793-1804), 10.1007/s00277-020-04149-5)
Annals of Hematology
-
Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group
British Journal of Haematology, Vol. 192, Núm. 3, pp. 522-530
-
Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis
Leukemia, Vol. 35, Núm. 1, pp. 245-249
-
Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development
Blood, Vol. 138, Núm. 17, pp. 1583-1589
2020
-
Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
Annals of Hematology, Vol. 99, Núm. 8, pp. 1793-1804
-
Biological and clinical significance of dysplastic hematopoiesis in patients with newly diagnosed multiple myeloma
Blood, Vol. 135, Núm. 26, pp. 2375-2387
-
Pembrolizumab as consolidation strategy in patients with multiple myeloma: Results of the GEM-pembresid clinical trial
Cancers, Vol. 12, Núm. 12, pp. 1-13
2019
-
Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma
Blood, Vol. 134, Núm. 16, pp. 1337-1345
-
Correction: Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role (Leukemia, (2018), 32, 11, (2427-2434), 10.1038/s41375-018-0072-6)
Leukemia
-
Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis
Leukemia, Vol. 33, Núm. 5, pp. 1256-1267
-
Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
Blood Cancer Journal, Vol. 9, Núm. 4
-
Response to Novel Drugs before and after Allogeneic Stem Cell Transplantation in Patients with Relapsed Multiple Myeloma
Biology of Blood and Marrow Transplantation, Vol. 25, Núm. 9, pp. 1703-1712
2018
-
Early myeloma-related death in elderly patients: development of a clinical prognostic score and evaluation of response sustainability role
Leukemia, Vol. 32, Núm. 11, pp. 2427-2434
-
Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials
PLoS ONE, Vol. 13, Núm. 9